Life Sciences
Our global Life Sciences practice comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, veterinary, medtech, diagnostics and healthcare sectors.
The practice operates on a cross-border basis and covers the full spectrum of legal support. We advise on mergers and acquisitions, commercial transactions (including licensing and collaborations), IP (both contentious and non-contentious), capital markets and finance, regulatory and dispute resolution. Our international network ensures that we have a ready resource of expertise in a number of jurisdictions, including those in emerging markets, and that we are well positioned to advise on cross-border work.
We have won a reputation for providing far-sighted advice to some of the world’s leading life science companies.
Explore our sectors
Meet our lawyers
市場讚譽
I have used Allen & Overy for coordinating EU cases. They have extensive knowledge of coordinating litigation.
Clients quoted in Chambers Global 2021 (Life Sciences: Global-wide)
They are well equipped to explain and navigate the different local jurisdictions to help towards a better understanding of various markets.
Client quoted in Chambers Europe 2021 (Intellectual Property: Europe-wide)
Strong European offering with noted expertise in IP and patent litigation matters. Well regarded for its impressive client portfolio, which spans the pharmaceutical, biotechechnology, medtech, diagnostics and healthcare industries. Also offers impressive expertise in commercial transactions and M&A.
Chambers Global 2018 (Life Sciences: Global-wide)
Related links
Life Sciences Talk
We report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector.
Read moreCRISPR microsite
The characterisation and optimisation of the CRISPR (also known as CRISPR-Cas) system for gene editing and other applications, is undoubtedly one of the most powerful and ground breaking advances in the history of biotechnology.
Go to micrositeRelated content
Global trends in merger control enforcement
Record levels in the first half of 2018 and considerable contraction in the second.